GlassScriptPhysician profile
Marek Piekos
NPI 1295756302
$11,110.39
in general payments reported to CMS, 2019-2025
44 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 92% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $483 · 2021: $2,311 · 2022: $2,771 · 2023: $1,398 · 2024: $1,210 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,851.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.00 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $741.00 | 2019-2024 | |
| Eisai INC. | $601.50 | 2019-2025 | |
| Sk Life Science, INC. | $589.29 | 2020-2025 | Xcopri |
| Lundbeck LLC | $583.19 | 2021-2025 | Vyepti |
| Amgen INC. | $490.31 | 2019-2024 | Uplizna |
| Genzyme Corporation | $477.80 | 2019-2023 | |
| Harmony Biosciences LLC | $474.79 | 2021-2024 | Wakix |
| Alexion Pharmaceuticals, INC. | $471.69 | 2019-2023 | Ultomiris |
| Lilly USA, LLC | $458.85 | 2019-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $418.02 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Csl Behring | $405.96 | 2022-2025 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $398.63 | 2021-2022 | |
| Greenwich Biosciences, INC. | $338.57 | 2019-2021 | |
| Acorda Therapeutics, INC | $327.10 | 2021-2024 | Inbrija, Ampyra |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marek Piekos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.